Articles - Page 45 of 101 - Drugs in Context

Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm

Xavier Garcia-Moll, Vivencio Barrios, Josep Franch-Nadal

Article Type

Commentary

Published

18 Aug 2021

This article discusses how patients with diabetes should be treated
according to their CV risk considered as a continuum and not simply as falling within primary or secondary prevention.

Response to ‘Presentation and pathophysiology of neuro-COVID’

Daniele Orsucci, Marco Vista

Article Type

Letter-to-the-Editor

Published

16 Aug 2021

Letter to the Editor in response to Finsterer J, Scorza FA, Scorza CA. Presentation and pathophysiology of neuro-COVID. Drugs Context. 2021;10:2021-6-5

Presentation and pathophysiology of neuro-COVID

Josef Finsterer, Fulvio Alexandre Scorza, Carla Alexandra Scorza

Article Type

Letter-to-the-Editor

Published

12 Aug 2021

Letter to the Editor commenting on Orsucci D, Caldarazzo Ienco E, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020;9:2020-5-1.

Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions

Amalia Leceta, Aintzane García, Ander Sologuren, Cristina Campo

Article Type

Review

Published

10 Aug 2021

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma

Francesco Serra, Carlotta Faverio, Angioletta Lasagna, Stefania Barruscotti, Tommaso Dominioni, Marco Benazzo, Paolo Pedrazzoli, Silvia Chiellino

Article Type

Review

Published

09 Aug 2021

The aim of this review is to investigate the role of treatment beyond progression and locoregional approaches in BRAF-mutated metastatic melanoma and provide oncologists dealing with this malignancy a useful road map on when and why to choose this strategy.